Literature DB >> 1936069

New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol.

F Leca1, D Marchiset-Leca, A Noble, M Antonetti.   

Abstract

Twenty-two days after administration by intravenous bolus, of 50 mg of adriamycin to several patients we found concentrations of adriamycin and adriamycinol of the order of 100 pcg/ml. In theory, however, with a terminal half-life of 30 h, the plasma levels of adriamycin and adriamycinol should be close to 0.1 pcg/ml. Further pharmacokinetic investigation was therefore necessary. We have retained for this study nine male patients, aged between 53 and 69 years who received 25 to 50 mg of adriamycin by slow intravenous injection. The HPLC method permitted the detection of 50 pcg/ml of adriamycin and adriamycinol, with the possibility of monitoring their elimination during 120 h (and in one case during 160 h). The terminal half-lives of elimination estimated in 8 patients were respectively 110 +/- 52 h for adriamycin and 92 h 50 min +/- 43 h for adriamycinol. Surface ratios under adriamycinol curves against calculated adriamycin was 1.10 +/- 0.26. Plasma levels found during the To in certain patients correspond to the end of the drug elimination of the previous treatment. It is difficult with a half-life to 110 h to predict the effects of residual concentrations of adriamycin and adriamycinol.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936069     DOI: 10.1007/BF03189946

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  9 in total

1.  Pharmacokinetics of doxorubicin in man with induced acid or alkaline urine.

Authors:  A Krarup-Hansen; K Wassermann; S N Rasmussen; M Dalmark
Journal:  Acta Oncol       Date:  1988       Impact factor: 4.089

2.  [Recent data on anthracyclines].

Authors:  M Marty; M Espie; C Gisselbrecht; G Lagier
Journal:  Pathol Biol (Paris)       Date:  1987-01

3.  [Pharmacokinetics and metabolism of anthracyclines in man].

Authors:  J Robert
Journal:  Pathol Biol (Paris)       Date:  1987-01

4.  Acute anthracycline cardiotoxicity. Comparative morphologic study of three analogues.

Authors:  A L Taylor; M M Applefeld; P H Wiernik; L B Grochow; L C Mader; B H Bulkley
Journal:  Cancer       Date:  1984-04-15       Impact factor: 6.860

5.  Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

Authors:  K Mross; P Maessen; W J van der Vijgh; H Gall; E Boven; H M Pinedo
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

6.  Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

Authors:  C M Camaggi; R Comparsi; E Strocchi; F Testoni; B Angelelli; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 7.  [Pharmacokinetics of new anthracyclines].

Authors:  J Robert
Journal:  Bull Cancer       Date:  1988       Impact factor: 1.276

8.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  [Cardiotoxicity of anthracyclines].

Authors:  S Laurent; N Colbert; V Izrael; G Motte
Journal:  Ann Med Interne (Paris)       Date:  1984
  9 in total
  4 in total

1.  Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.

Authors:  Jonás Samuel Pérez-Blanco; Dolores Santos-Buelga; María Del Mar Fernández de Gatta; Jesús María Hernández-Rivas; Alejandro Martín; María José García
Journal:  Br J Clin Pharmacol       Date:  2016-09-06       Impact factor: 4.335

2.  A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.

Authors:  D Marchiset-Leca; F R Leca; A Galeani; A Noble; A Iliadis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.

Authors:  D Marchiset-Leca; F R Leca; A Galeani; A Noble; J Catalin
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

Authors:  H Rosing; W W ten Bokkel Huinink; R van Gijn; R F Rombouts; A Bult; J H Beijnen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jan-Mar       Impact factor: 2.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.